Evidence map›Paper›PMID 27116664›Full record

ReviewInvestigative ophthalmology & visual science2016

Photoreceptor Transplantation in Late Stage Retinal Degeneration.

Thomas A Reh

Abstract readReview
In one paragraph

Review in Investigative ophthalmology & visual science, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 34 papers.

0numbers the graph read from it
0cells of the map it votes in
34citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

34 citing papers in PubMed.

  1. Review
  2. Article
  3. Review
  4. Review
  5. Article
  6. Review
  7. Review
  8. Article
  9. Review
  10. Current and Future Treatment of Retinitis Pigmentosa.Clinical ophthalmology (Auckland, N.Z.) · 2022
    Article
  11. Article
  12. Review
  13. Outer Retinal Cell Replacement: Putting the Pieces Together.Translational vision science & technology · 2021
    Review
  14. Article
  15. Article
  16. Article
  17. Review
  18. Article
  19. Article
  20. MiRNA Regulatory Functions in Photoreceptors.Frontiers in cell and developmental biology · 2020
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

1 author.

Thomas A Reh

Funding

Supplement to EY021482 to carry out a screen for retinal regeneration using CRISPR-Cas9 gene activation.R01EY021482 · NEI · UNIVERSITY OF WASHINGTON · PI THOMAS A REH · 2011 to 2026
$6.3M
NEI NIH HHS R01 EY021482
6 · The paper itself

Abstract

The recent advances in cell-based therapies for the repair of the pigmented epithelium is providing additional impetus for the translation of photoreceptor transplantation to eventual clinical trials. The prospects for transplantation of photoreceptors as a potential therapy for the treatment of photoreceptor degeneration will depend on successfully addressing many critical issues in preclinical studies. Although most of the studies that have carried out transplants of photoreceptors have primarily used normal mice, there have been recent reports that have also shown some success following transplantation to mouse models of retinitis pigmentosa. However, while these results are promising, there are several key issues that require further investigation in order to better understand the optimum timing for transplantation, given the extensive remodeling of the retina that occurs in late stage disease.

Indexed as

AnimalsCell TransplantationDisease Models, AnimalMicePhotoreceptor Cells, VertebrateRetinaRetinal Degeneration

Identifiers

PMID27116664
PMCPMC5992960

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.